NEW YORK, Nov. 10, 2014 /PRNewswire/ -- Key Findings
•Chronic obstructive pulmonary disorder (COPD) is the third leading cause of death in the United States, and is in fourth place in Europe and the rest of the world.
•An estimated xxmillion people are affected by COPD globally. By 2020, COPD is projected to be the third leading cause of death globally.
•Limited communication between medical practitioners and patients limits early diagnosis of the disease.
•It is estimated that only xx% of smokers detect the onset of COPD symptoms and seek medical advice and treatment.
•Bronchodilators, anti-inflammatories, and combination therapies are prime segments used in evaluating asthma and COPD therapeutics.
•Combination therapies such as Symbicort Turbuhaler, Relvar Ellipta, and Anoro Ellipta show promising market acceptance due to increased clinical benefits of higher drug efficacy, especially in patients with increased disease severity.
•Bronchodilators are widely used to manage mild to moderate symptoms associated with COPD.
•Patent expiration of blockbuster drugs such as Advair (known as Seretide in the European Union) widen pipeline investment opportunities to meet therapeutic demand.
•Teva Pharmaceuticals, AstraZeneca, Novartis, Merck & Co., and Boehringer Ingelheim are among the Tier I participants in this market.
•Upcoming drugs include:
oDuoResp Spiromax, an inhaled corticosteroid and long-acting beta2-adrenoceptor agonist combination therapy drug by Teva Pharmaceuticals (approved, pending launch).
oStriverdi Respimat (olodaterol), a bronchodilator by Boehringer Ingelheim (approved, pending launch).
oBenralizumab, a monoclonal antibody jointly being developed by MedImmune and AstraZeneca in Phase 3 trials. Benralizumab is bound to the interleukin-5 receptor (IL-5R?) and is being evaluated to help asthma control and reduce the onset of asthmatic attacks.
oNovartis' QMF149 Twisthaler is under drug safety trial to assess its effect on asthma exacerbations, and is expected to arrive in the market by 2017.
•Striverdi Respimat is approved in the United Kingdom, Denmark, and Iceland based on results obtained from Phase 3 trials, which displayed remarkable improvements in lung functions with the use of the drug as an addition to the usual care drugs in COPD patients. The estimated launch in the United States and Japan is expected to be either in the last quarter of 2014 or the first quarter of 2015.
•GSK and Theravance's jointly developed drug, GSK961081, is classified as a bifunctional molecule developed with muscarinic antagonist and ?2-agonist (MABA) properties to be used by COPD patients. It is in Phase 2 in Australia.
Development of innovative COPD therapeutics to check inflammations and exacerbations in patients will increase.
The patent expiry of blockbuster drugs such as Advair opens investment opportunities for strengthening pipeline portfolios to meet the rising drug demands.
Interest in developing combination therapies is growing because of their higher therapeutic efficacy.
The high economic burden due to the rise of COPD incidence creates tremendous investment opportunities.
Limited knowledge of the disease, limited drug classes, and an absence of a permanent cure increases investment interest in the market.
Read the full report: http://www.reportlinker.com/p02464464-summary/view-report.html
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: [email protected]
Intl: +1 339-368-6001